Starting from an overview of the performance of EEMEAI Hemostasis, with significant milestones reached in 2021 like 500+ ACL TOP 50 Series instruments shipped since the launch of the family of instruments in 2015 and 1000+ ACL TOP 50 Series and 00 Series since 2015.
We also reviewed in detail the performance of Reagent families starting from the striking increase of demand of D-Dimer assays to manage the COVID19 situation followed by the Routine assays, Bleeding Assays, Thrombophilia, APS, Heparin, HIT and ADAMTS13.
We spent time reviewing the Hemostasis Priorities for 2021 in view of market pressures, starting from HemoCell with the positioning in the high value accounts. The role of the HemoHub in managing the consolidation of labs. The role AcuStar and its specialized panel of assays in standardizing highly specialized assays in University hospitals and specialized centers. An update on supporting material available to convey the differentiated value of the ACL TOP 50 series, and an overview of AccuTrak 2.0.
We continued with a competitive update on systems, automation and reagents delivered by the Werfen SBU Hemostasis Team based in the USA. This was further supported by a database of competition material now available on Werfen Docs.
Additionally, we introduced an upcoming tool that will assist teams in the field in their interactions with customers, Werfen Touch. Following this introduction, Stefano FialĂ and Davide Pesenti Barili performed demonstrations of the Value Calculators. They shared how to use 4 out of 8 calculators available, the HIT Assays Value Calculator, the Maintenance Value Calculator, the ADAMTS13 Value Calculator, and the Turnaround Time Calculator. The feedback was quite positive, and the demand for the launch of Werfen Touch was clear.
We wrapped up our sessions on May 27th with 3 experiences, the first was delivered by a joint presentation by Haitham Al Kazzaz, Business Unit Manager at Abdulla Fouad for Medical Supplies and Services Company and Stefano Fiala, who took us through the deployment plans for Automation and Middleware in the Kingdom of Saudi Arabia and the approach that includes building internal capabilities and finding the right customers for each solution. The second experience comes from Raffael Frei, head of sales at AxonLab, who took us through his experience positioning and the success he had in Switzerland in placing ACL AcuStar in specialized centers and showcasing the success of the adoption of the HemosIL AcuStar ADAMTS13 Activity. Our third and final experience was focused on AccuTrak 2.0 as part of quality management in Hemostasis Labs.
Stay Safe and Take Care of Each Other.
See you soon and hopefully in person.
Hemostasis Marketing Team